OGeS Raises Equity Funding for Dx Development | GenomeWeb
NEW YORK (GenomeWeb News) - Oxford Genome Sciences today said it has received an equity placement from three investors, including previous investors South East Growth Fund and Oxford Capital Partners, and first-time investor Catapult Growth Fund.
A company spokesperson declined to disclose the amount of the financing.
OGeS develops disease-related proteins for use in cancer diagnostics and therapeutics.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.

A cancer researcher retracts 19 articles from one journal for image manipulation, according to Retraction Watch.

Precision medicine has to consider context in addition to genetic mutations in cancer treatment, Medscape reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.